These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Combined hepatocellular-cholangiocarcinoma (cholangiolocellular type) with stem-cell features: a clinicopathologic analysis of 26 cases]. Xu J; Zhang C; Qiao A; Xi Y Zhonghua Bing Li Xue Za Zhi; 2016 Mar; 45(3):175-9. PubMed ID: 26956962 [TBL] [Abstract][Full Text] [Related]
5. The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection. Matsubara K; Kobayashi T; Tadokoro T; Namba Y; Fukuhara S; Oshita KO; Honmyo N; Kuroda S; Arihiro K; Ohdan H Anticancer Res; 2024 Oct; 44(10):4551-4559. PubMed ID: 39348996 [TBL] [Abstract][Full Text] [Related]
6. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Komuta M; Spee B; Vander Borght S; De Vos R; Verslype C; Aerts R; Yano H; Suzuki T; Matsuda M; Fujii H; Desmet VJ; Kojiro M; Roskams T Hepatology; 2008 May; 47(5):1544-56. PubMed ID: 18393293 [TBL] [Abstract][Full Text] [Related]
9. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
10. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Sasaki M; Sato Y; Nakanuma Y Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. Chen J; He J; Deng M; Wu HY; Shi J; Mao L; Sun Q; Tang M; Fan XS; Qiu YD; Huang Q Hum Pathol; 2017 Jun; 64():118-127. PubMed ID: 28431889 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic study on cholangiolocellular carcinoma. Shiota K; Taguchi J; Nakashima O; Nakashima M; Kojiro M Oncol Rep; 2001; 8(2):263-8. PubMed ID: 11182037 [TBL] [Abstract][Full Text] [Related]
14. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features. Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316 [TBL] [Abstract][Full Text] [Related]
15. Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas. Kikuchi AT; Umetsu S; Joseph N; Kakar S Am J Surg Pathol; 2023 Nov; 47(11):1207-1218. PubMed ID: 37661782 [TBL] [Abstract][Full Text] [Related]
16. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764 [TBL] [Abstract][Full Text] [Related]
17. Distinctive clinicopathological features and KRAS and IDH1/2 mutation status of cholangiolocellular carcinoma. Kusano H; Naito Y; Mihara Y; Kondo R; Ogasawara S; Akiba J; Nakashima O; Yano H Hepatol Res; 2020 Jan; 50(1):84-91. PubMed ID: 31733634 [TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities. Zen Y Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170 [TBL] [Abstract][Full Text] [Related]
20. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma. Sasaki M; Sato Y; Nakanuma Y Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]